Sarepta Therapeutics CEO Doug Ingram is taking the high road.
In remarks Thursday on a quarterly earnings call, Ingram refused to criticize the Food and Drug Administration for rejecting Sarepta’s Duchenne muscular dystrophy drug Vyondys 53.
“We were treated fairly by the division of neurology,” he said, referring to the group of reviewers within the FDA who reviewed Vyondys but turned the drug away in August, citing the risk of infections related to intravenous infusion ports and kidney toxicity seen in animal experiments.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect